Summit Therapeutics (SMMT) Reports Q3 Loss of GBP0.08/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Summit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2015 and Operational Progress
December 17, 2015 7:00 AM ESTOXFORD, United Kingdom, Dec. 17, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM: SUMM) (NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (DMD) and C. difficile infection (CDI), today reports its financial results for the third quarter ended 31 October 2015.
Mr Glyn Edwards, Chief Executive Officer of Summit commented: We have recently announced positive clinical trial results for both our lead programmes in DMD and CDI, enabling us to advance these promising candidates to... More
